Stocks in play: Marvel Biosciences Corp
Announces that along with its wholly owned subsidiary, Marvel Biotechnology Inc., it has completed the dosing portion of the 4-week good laboratory practice FDA investigational new drug enabling dose-ranging dog and rat studies for its lead drug candidate MB-204. MB-204 is a fluorinated derivative of the U.S. FDA-approved adenosine A2a receptor antagonist, Istradefylline. Both Istradefylline and MB-204 are highly active derivatives of caffeine, the most widely consumed psychoactive drug in the world. Caffeine consumption has been associated with a reduced risk of developing Parkinson's disease, and Alzheimer's disease and improved concentration. Marvel Biosciences Corp shares V.MRVL are trading unchanged at $0.10.
Read:
Global Lithium Supply Under Pressure as South American Nations Discuss "Lithium OPEC"
International Lithium Buyers Looking to South America to Fill Supply Gaps
Race to Secure Critical EV Battery Metals Ahead of Chinese Dominance Fully Underway
Help is on the Way as Rising Alzheimer’s Cases Highlight Urgency for New Treatments
FDA’s Wave of Fast Track Designations Pushing Momentum in Healthcare Sector in 2023